A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer (CRPC)

Trial Profile

A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer (CRPC)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Jun 2017

At a glance

  • Drugs Abiraterone acetate (Primary) ; Prednisone
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 24 Jun 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 23 Oct 2013 New source identified and integrated (Oregon Health and Science University Institutional Review Board; IRB00008787).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top